Clinical Research Directory

Inclusion Criteria: 1. Adults aged 18-65 diagnosed with Alopecia Areata (patchy or extensive) up to 10 years 2. Willingness to adhere to study protocols, including FMT administration via capsules or colonoscopy. 3. Ability to sign informed consent. 4. SALT score≥ 20 Exclusion Criteria: 1. History of gastrointestinal disorders (e.g., IBD, celiac disease). 2. Recent use of antibiotics, probiotics, or prebiotics (within 2 months). 3. Pregnant or breastfeeding women of childbearing potential who are unwilling or unable to use an acceptable method of birth control. 4. Individuals with immunocompromised or immunosuppressed states (e.g., HIV, cancer). 5. Prior FMT treatment for any condition. 6. Therapy with new antidepressants or had a change in antidepressant dose within previous 3 months 7. Serious medical comorbidities(including neurological or phychiatric comorbidities) 8. Elevated C-reactive protein concentration, abnormal baseline laboratory tests 9. Severe(anaphylactic) food allergy 10. Concomitant treatments for AA: topical KS 1 week prior to randomization, topical JAK inhibitor, diphenylcyclopropenone, or other topical immunotherapies within 4 weeks prior to randomization;systemic corticosterids, immunosuppressant, intra-lesional or intra-articular corticosteroid injections, or oral JAK inhibitor within 8 weeks prior to randomization;monoclonal antibody \<5 half-lives prior to randomization; probenecid at the time of randomization. Bimatoprost ophtalmic solution was allowed if on stable dose for 8 weeks.